Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.

Trial Details

NCT ID

NCT05174169

Phase

PHASE2 / PHASE3

Sponsor

NRG Oncology

Status

RECRUITING

Cancer Type

Colorectal Cancer

Interventions

Signatera test
mFOLFOX6 3-6 month
CAPOX 3 month
mFOLFIRINOX
mFOLFOX6 6 month
CAPOX 6 month

Locations (sample)

Birmingham, Alabama, United States|33.52066,-86.80249
Fairhope, Alabama, United States|30.52297,-87.90333
Mobile, Alabama, United States|30.69436,-88.04305
Mobile, Alabama, United States|30.69436,-88.04305
Kingman, Arizona, United States|35.18944,-114.05301

Key Eligibility Criteria

The patient must have an ECOG performance status of 0 or 1.
Patients must have histologically/pathologically confirmed Stage IIB, IIC, or Stage III colon adenocarcinoma with R0 resection according to AJCC 8t…
No radiographic evidence of overt metastatic disease within 45 days prior to Step 1/Study entry (CT with IV contrast or MRI imaging is acceptable a…
The distal extent of the tumor must be greater than or equal to 12 cm from the anal verge on colonoscopy or above the peritoneal reflection as docu…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →